Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.

Driven by its lower costs and high response rates, brodalumab was the most cost-effective treatment option for moderate to severe plaque psoriasis over a one-year time-horizon within the anti-IL17 class and when compared to all other biologics in France and Germany.